BioCryst Pharmaceutical Inc. (BCRX)

Sector:

HEALTH CARE

Industry:

PHARMACEUTICALS

SIC:

BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

CEO:

Jon P. Stonehouse

Employees:

530

4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC 27703

919-859-1302

BioCryst Pharmaceuticals, Inc. discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases. Galidesivir, a RNA dependent-RNA polymerase inhibitor, is in clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola,

Data derived from most recent annual or quarterly report
Market Cap	1.342 Billion	Shares Outstanding	189.494 Million	Avg 30-day Volume	2.522 Million
P/E Ratio	0.0	Dividend Yield	0.0	EPS	-0.4
Price to Revenue	4.3419	Debt to Equity	-0.7692	EBITDA	-11.055 Million
Price to Book Value	0.0	Operating Margin	-36.809799999999996	Enterprise Value	1.215 Billion
Current Ratio	5.466	EPS Growth	-0.122	Quick Ratio	5.009
1 Yr BETA	0.9647	52-week High/Low	14.5 / 6.62	Profit Margin	-79.1545
Operating Cash Flow Growth	23.977	Free Cash Flow to Firm (FCFF) TTM	-55.038 Million	Free Cash Flow to Equity (FCFE) TTM	565.33 Million
Altman Z-Score	-2.4922
Earnings Report	2023-11-01

View SEC Filings from BCRX instead.

View recent insider trading info

BioCryst Pharmaceutical Inc. YCharts
Yahoo! Finance	finviz
SEC Web Site	SEC DEF 14A Filings

Funds Holding BCRX (via 13F filings)

Quarter to view: Refresh Download CSV Download Excel (.xlsx) Download TSV

Click for Additional Filters

Market Value:

to

Ranking:

to

% of portfolio

to

*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BCRX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

4: filed on 2023-09-05 by MILANO VINCENT

4: filed on 2023-09-05 by HEGGIE THERESA

4: filed on 2023-06-15 by STONEHOUSE JON P

4: filed on 2023-06-15 by LEVIN ALAN G

4: filed on 2023-06-15 by LEE KENNETH B JR

4: filed on 2023-06-15 by GALSON STEVEN K

4: filed on 2023-06-15 by ASELAGE STEVE

4: filed on 2023-06-15 by SANDERS MACHELLE

4: filed on 2023-06-15 by MILANO VINCENT

4: filed on 2023-06-15 by HUTSON NANCY J

Events (8k)

8-K: filed on 2023-08-03:

Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

8-K: filed on 2023-07-11:

Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K: filed on 2023-06-14:

Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

8-K: filed on 2023-05-03:

Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

8-K: filed on 2023-04-18:

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

8-K: filed on 2023-03-13:

Item 7.01: Regulation FD Disclosure

8-K: filed on 2023-02-21:

Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

8-K: filed on 2023-01-09:

Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

8-K: filed on 2022-12-15:

Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

8-K: filed on 2022-11-01:

Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Proposed Sales (Form 144)

144: filed on 2023-06-14:

144: filed on 2023-06-15:

Proxy

Prospectus

All

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name	Type	Last Reported Shares Held	Last Reported Date	Filings in past year
MILANO VINCENT	Director	50,042	2023-08-31	5
HEGGIE THERESA	Director	49,905	2023-08-31	5
LEVIN ALAN G	Director	37,090	2023-06-13	4
LEE KENNETH B JR	Director	68,863	2023-06-13	2
ASELAGE STEVE	Director	63,339	2023-06-13	1
HUTSON NANCY J	Director	81,818	2023-06-13	1
STONEHOUSE JON P PRESIDENT & CEO	Officer Director	1,024,794	2023-06-13	6
ABERCROMBIE GEORGE B	Director	29,611	2023-06-13	1
GALSON STEVEN K	Director	29,611	2023-06-13	1
SANDERS MACHELLE	Director	25,611	2023-06-13	1
MCKEE AMY E	Director	29,611	2023-06-13	1
THACKRAY HELEN M. CHIEF R&D OFFICER	Officer	207,275	2023-04-03	3
INGRAM ROBERT ALEXANDER	Director	100,198	2023-02-28	2
BARNES ALANE P CHIEF LEGAL OFFICER	Officer	391,270	2022-12-19	2
JONES MICHAEL L EXEC. DIRECTOR, FINANCE - PAO	Officer	25,153	2022-12-19	3
GAYER CHARLES K CHIEF COMMERCIAL OFFICER	Officer	404,110	2022-12-19	2
DOYLE ANTHONY CHIEF FINANCIAL OFFICER	Officer	356,466	2022-12-19	2
BABU YARLAGADDA S CHIEF DISCOVERY OFFICER	Officer	298,541	2022-11-14	1
SHERIDAN WILLIAM P CHIEF MEDICAL OFFICER	Officer	37,954	2022-03-10	0
SNIECINSKI MEGAN CHIEF BUSINESS OFFICER	Officer	0	2020-12-15	0
STAAB THOMAS R II SENIOR VICE PRESIDENT AND CFO	Officer	0	2020-02-21	0
POWELL LYNNE SENIOR VP - CCO	Officer	164,854	2019-01-25	0
ERCK STANLEY C	Director	48,333	2018-11-28	0
COHEN FRED E	Director	0	2018-06-20	0
PATEL SANJ K	Director	0	2017-05-24	0
BAKER BROS. ADVISORS LP BAKER BROS. ADVISORS (GP) LLC BAKER JULIAN BAKER FELIX	10% Owner	11,016,695	2016-08-12	0
SANDERS CHARLES A	Director	12,971	2016-02-29	0
JENSEN PEDER	Director	0	2014-05-02	0
BAKER FELIX BAKER BROS. INVESTMENTS II, L.P. BAKER/TISCH INVESTMENTS, LP 667, L.P. BAKER BROTHERS LIFE SCIENCES LP 14159, L.P. BAKER BROS. ADVISORS LP BAKER JULIAN BAKER BROS. ADVISORS (GP) LLC BAKER BROS. INVESTMENTS, L.P.	10% Owner	6,648,692	2013-08-01	0
BAKER BROS. ADVISORS (GP) LLC	10% Owner	0	2013-07-01	0
HOROVITZ ZOLA P	Director	0	2012-05-23	0
HIGGINS JOHN L	Director	0	2012-05-23	0
BAKER BROS ADVISORS LLC	10% Owner	0	2012-04-12	0
LOWREY ROBERT S CONTROLLER, PAO	Officer	9,766	2012-03-15	0
MCCULLOUGH DAVID VP	Officer	24,124	2012-03-15	0
BAKER BROS. CAPITAL (GP), LLC BAKER JULIAN BAKER FELIX	10% Owner	62,407	2011-06-30	0
BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC BAKER JULIAN BAKER FELIX	10% Owner	3,841,124	2011-06-30	0
BIGGAR STEPHEN R	Director	0	2011-05-12	0
GRANT STUART SR VP & CFO	Officer	57,102	2011-03-16	0
FEATHERINGILL WILLIAM W	Director 10% Owner	0	2010-05-13	0
SEIDENBERG BETH C	Director	0	2010-05-13	0
MILLS MIKE PRINCIPAL ACCOUNTING OFFICER	Officer	0	2010-03-12	0
BAKER BIOTECH CAPITAL (GP), LLC BAKER JULIAN BAKER FELIX	10% Owner	1,522,015	2009-05-28	0
BAKER / TISCH CAPITAL (GP), LLC BAKER JULIAN BAKER FELIX	10% Owner	17,241	2009-05-28	0
14159 CAPITAL (GP), LLC BAKER JULIAN BAKER FELIX	10% Owner	120,828	2009-05-28	0
DARWIN MICHAEL A PRINCIPAL ACCOUNTING OFFICER	Officer	3,048	2008-07-31	0
STEER RANDOLPH C	Director	0	2008-05-21	0
BENNETT J CLAUDE CHIEF OPERATING OFFICER	Officer Director	0	2008-03-14	0
ALEXANDER W JAMES SR. VP, CHIEF MEDICAL OFFICER	Officer	3,659	2007-07-31	0
NUGENT JONATHAN M VP CORP COMMUNICATIONS	Officer	508	2007-07-31	0
SHERRILL JOSEPH H JR	Director	15,000	2007-05-16	0
SPENCER WILLIAM M III	Director	15,000	2007-05-16	0
RIGGS RANDALL B SENIOR VP BUSINESS DEVELOPMENT	Officer	23,868	2007-05-16	0

Insider Transactions Last 60 Days

Reporting Owners	Filing Date	Trans Date	Trans Code	Shares	Share Price	Acquired Disposed	Shares Owned after	D/I	10b5	Perf 1d*	Perf 5d*	Perf 1m*	Max Gain	Max Gain Days	Max Loss	Max Loss Days
HEGGIE THERESA - Director	2023-09-05 16:41:49 -0400	2023-08-31	A	791	$7.11	a	49,905	direct		-2.1429	-1.7143		1.1429	3	-2.2857	4
MILANO VINCENT - Director	2023-09-05 16:43:39 -0400	2023-08-31	A	791	$7.11	a	50,042	direct		-2.1429	-1.7143		1.1429	3	-2.2857	4

* -

Transaction Code Definitions
Code	Definition
A	Grant, award or other acquisition pursuant to Rule 16b-3(d)
C	Conversion of derivative security
D	Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E	Expiration of short derivative position
F	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G	Bona fide gift
H	Expiration (or cancellation) of long derivative position with value received
I	Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J	Other acquisition or disposition
L	Small acquisition under Rule 16a-6
M	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O	Exercise of out-of-the-money derivative security
P	Open market or private purchase of non-derivative or derivative security
S	Open market or private sale of non-derivative or derivative security
U	Disposition pursuant to a tender of shares in a change of control transaction
W	Acquisition or disposition by will or the laws of descent and distribution
X	Exercise of in-the-money or at-the-money derivative security
Z	Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security	Date/Time	Rebate Rate	Fee Rate	Shares Available
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 22:15:03 UTC	4.0899	1.2301	3500000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 21:45:03 UTC	4.0899	1.2301	3500000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 21:15:04 UTC	4.0899	1.2301	3500000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 20:45:04 UTC	4.0899	1.2301	3500000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 20:15:03 UTC	4.1473	1.1727	3500000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 19:45:03 UTC	4.1473	1.1727	3500000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 19:15:03 UTC	4.1473	1.1727	3500000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 18:45:04 UTC	4.1473	1.1727	3500000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 18:15:04 UTC	4.1473	1.1727	3500000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 17:45:04 UTC	4.9714	0.3486	3500000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 17:15:03 UTC	4.9714	0.3486	3500000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 16:45:04 UTC	4.9714	0.3486	3500000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 16:15:04 UTC	4.9714	0.3486	3500000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 15:45:04 UTC	4.9714	0.3486	3400000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 15:15:04 UTC	4.9714	0.3486	3400000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 14:45:03 UTC	4.9542	0.3658	3400000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 14:15:03 UTC	4.9542	0.3658	3400000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 13:45:04 UTC	4.9542	0.3658	3400000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 13:15:05 UTC	4.9542	0.3658	3400000
BIOCRYST PHARMACEUTICALS INC BCRX	2023-10-02 12:45:05 UTC	4.9542	0.3658	3400000

Current Active Short Positions

Holder	Issuer	Net Short Position	Position Date	Origin

No recent transactions

* To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page*

Elevate your investments